The revised EBM catalog came into force in Germany in October 2021

01

Nov 2021

The reimbursement of services in the public outpatient sector in Germany is regulated in the EBM catalog (Einheitlicher Bewertungsmaßstab), updated once in a quarter (4 times a year). The adaption time frame of the EBM catalog for a specific code is around five years but varies depending on the evidence. The latest EBM (German Uniform Evaluation Standard) catalog came into force on Щсещиук 1, 2021.

The most significant introduced changes concern mainly IVD tests: extension of the newborns screening by the inclusion of the tests for sickle cell disease and 5q-associated spinal muscular atrophy, the introduction of microsatellite instability testing, amendments of Oncotype DX® test reimbursement, the introduction of screening for hepatitis B and C as part of health check-up, as well as changes in reimbursement of radiation therapy services.

The list of the most important changes in EBM for the fourth quarter of 2021 is presented below. The examples of the new codes introduced in the EBM catalog:

EBM sub-chapter 1.7.2 “Early detection of diseases in adults”

  • 01734 Surcharge for service 01732 (health check-up for people aged over 18) for screening for hepatitis B and/or hepatitis C with a tariff of €4.56;
  • 01744 Screening for hepatitis B and/or hepatitis C as part of the transitional arrangement with a tariff of €4.56;
  • 01865 Detection of HBs antigen and/or HCV antibodies with a tariff of €11.68;
  • 01866 Surcharge for service GOP 01865 for the determination of the hepatitis B virus DNA in the case of a reactive result of the examination for HBs antigen with a tariff of €89.55;
  • 01867 Surcharge for service 01865 for the nucleic acid detection of hepatitis C virus RNA in the case of the reactive result of the test for HCV antibodies with a tariff of €40.05;

EBM sub-chapter 19.4.4 “In-vitro diagnostics of tumor genetic changes to indicate pharmacological therapy”

  • 19464 “Microsatellite instability testing in the tumor material to indicate targeted drug treatment, if this is mandatory according to the specialist information, twice in the case of disease” with a tariff of €96.45;

EBM sub-chapter 25.3.4 “Radiation therapy planning”

  • 25345 “Computer-assisted radiation therapy planning for percutaneous radiation therapy with individual dose planning for soft radiation therapy or orthovoltage therapy” with a tariff of €117.25.

Also, the tariffs of multiple services (radiation therapy in benign and malignant diseases, radiation therapy planning) listed under the EBM chapter 25 “Radiotherapy fee order items” are decreased;. In contrast, the tariff for the service under the EBM code 25310 “Soft radiation therapy or orthovoltage therapy” is increased to €12.79 (the previous tariff amounted to €10.23).

The full details in German can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

20

May 2022

In April 2022, NHS England and NHS Improvement (NHSEI) announced that the timelines for the evaluation of applications to update the National Genomic Test Directory in 2022/23 are currently under review. Previously, NHSEI planned to publish and implement the 2022/23 Test Directory by April 2022. While the timelines are not confirmed, applications can still be submitted.

Read more

19

May 2022

On April 25, 2022, the Decision Forum for "New Method" did not prioritize any surgical procedure in the treatment of morbid obesity. Available evidence in the complete method assessment shows minor or no difference in weight loss, diabetes control, or health-related quality of life when using various surgical procedures. The comparative effect on the risk of early mortality, progression of obesity, and obesity-related comorbidities was not possible to determine. The cost differences are non-significant. Further research was recommended.

Read more

18

May 2022

On April 19, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) has informed of the favorable results of the scientific evaluation of the G-BA Innovation Fund performed by the economic research center Prognos AG.

Read more

17

May 2022

On April 21, 2022, NHS England and NHS Improvement updated the 2021/22 National Genomic Test Directory (version 3), which lists genomic tests commissioned by NHS England via Genomic Laboratory Hubs. Forty-two new codes (test-indication combinations) were introduced in the cancer field, and fourteen for rare and inherited diseases.

Read more

16

May 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in April 2022. Thirty recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, orthopedic, neurovascular, and neuromodulation and other devices, as well as medical aids.

Read more